机译:Pegilodecakin与Pembrolizumab或Nivolumab联合治疗晚期实体肿瘤的患者(常春藤):多期,多期,多级,开放标签,第1B期试验
Univ Texas MD Anderson Canc Ctr Houston TX 77030 USA;
Univ Calif Los Angeles David Geffen Sch Med TRIO US Los Angeles CA 90095 USA;
Sarah Cannon Res Inst Tennessee Oncol Nashville TN USA;
Univ Calif San Francisco San Francisco CA 94143 USA;
Sarah Cannon Res Inst Tennessee Oncol Nashville TN USA;
START Ctr Canc Care San Antonio TX USA;
Mem Sloan Kettering Canc Ctr 1275 York Ave New York NY 10021 USA;
Univ Texas MD Anderson Canc Ctr Houston TX 77030 USA;
Sarah Cannon Res Inst Tennessee Oncol Nashville TN USA;
Univ Calif Los Angeles David Geffen Sch Med TRIO US Los Angeles CA 90095 USA;
Univ Texas MD Anderson Canc Ctr Houston TX 77030 USA;
ARMO BioSci Redwood City CA USA;
ARMO BioSci Redwood City CA USA;
ARMO BioSci Redwood City CA USA;
ARMO BioSci Redwood City CA USA;
ARMO BioSci Redwood City CA USA;
Eli Lilly &
Co New York NY USA;
ARMO BioSci Redwood City CA USA;
Univ Texas MD Anderson Canc Ctr Houston TX 77030 USA;
Univ Calif Los Angeles David Geffen Sch Med TRIO US Los Angeles CA 90095 USA;
Univ Texas MD Anderson Canc Ctr Houston TX 77030 USA;
机译:Pegilodecakin与Pembrolizumab或Nivolumab联合治疗晚期实体肿瘤的患者(常春藤):多期,多期,多级,开放标签,第1B期试验
机译:Pembrolizumab在儿科患者中具有先进的黑色素瘤或PD-L1阳性,先进,复发或难治性实体肿瘤或淋巴瘤(Keynote-051):开放标签,单臂,第1-2期试验的临时分析
机译:Ramucirumab Plus Pembrolizumab患者以前治疗的晚期非小细胞肺癌,胃肠癌癌或尿路上皮癌(JVDF):多伐木菊,非随机化,开放标签,阶段1A / B试验
机译:患者临床试验与患有转移和/或复发性固体瘤的患者的HER-2 B细胞嵌合和多型肽疫苗
机译:患者参加I期试验期间,晚期癌症患者及其伴侣之间的沟通偏好,受益期望以及症状负担
机译:Epacadostat加Pembrolizumab治疗晚期实体瘤的患者:I期来自一项多中心开放标签的I / II期试验(ECHO-202 / KEYNOTE-037)
机译:儿童和年轻成年人的Nivolumab复发或难治性实体肿瘤或淋巴瘤(ADVL 1412):多中心,开放标签,单臂,第1-2期试验